NCT04307134 2025-12-31
Besponsa Post Marketing Surveillance Study
Pfizer
Completed
Clinical Trials
21 trialsNCT05687032 2025-12-03
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 4 Completed
NCT05597085 2025-02-04
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
Pfizer
Completed
NCT01664910 2024-07-23
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01134575 2024-07-16
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03488225 2024-07-16
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03677596 2023-11-22
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
Pfizer
Phase 4 Completed
NCT02311998 2023-07-17
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01925131 2023-05-03
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
SWOG Cancer Research Network
Phase 1 Completed
NCT04456959 2022-09-28
InO
Pfizer
Completed
NCT03094611 2021-04-12
Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01055496 2019-08-02
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Pfizer
Phase 1 Completed
NCT00724971 2019-03-15
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
Pfizer
Phase 1 Completed
NCT01564784 2019-01-09
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 3 Completed
NCT01232556 2019-01-08
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Pfizer
Phase 3 Terminated
NCT00073749 2018-12-17
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
Pfizer
Phase 1 Completed
NCT00299494 2018-03-08
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
Pfizer
Phase 1/2 Completed
NCT00562965 2018-01-09
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
Pfizer
Phase 3 Terminated
NCT00867087 2017-12-05
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Pfizer
Phase 2 Completed
NCT00868608 2017-10-31
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
Pfizer
Phase 2 Completed
NCT01363297 2017-04-13
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
Pfizer
Phase 2 Completed